Rapamycin promotes podocyte autophagy and ameliorates renal injury in diabetic mice

Molecular and Cellular Biochemistry

Volumn 394, Issue 1-2, 2014, Pages 145-154

  Xiao, Tangli ^a   Guan, Xu ^a   Nie, Ling ^a   Wang, Song ^a   Sun, Lei ^a   He, Ting ^a   Huang, Yunjian ^a   Zhang, Jingbo ^a   Yang, Ke ^a   Wang, Junping ^a   Zhao, Jinghong ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Autophagy; Diabetic nephropathy; mTOR signal pathway; Podocyte injury; Rapamycin

Indexed keywords

BAX PROTEIN, MOUSE; BIOLOGICAL MARKER; CASP3 PROTEIN, MOUSE; CASPASE 3; MAP1LC3 PROTEIN, MOUSE; MEMBRANE PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; NEPHRIN; PODOCIN; PROTEIN BAX; RAPAMYCIN; S6 KINASE; SIGNAL PEPTIDE;

ALBUMINURIA; ANIMAL; AUTOPHAGY; BAGG ALBINO MOUSE; BLOOD; CELL PROTECTION; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DRUG EFFECTS; MALE; METABOLISM; PATHOLOGY; PODOCYTE; TIME; ULTRASTRUCTURE; UREA NITROGEN BLOOD LEVEL;

ALBUMINURIA; ANIMALS; AUTOPHAGY; BCL-2-ASSOCIATED X PROTEIN; BIOLOGICAL MARKERS; BLOOD UREA NITROGEN; CASPASE 3; CYTOPROTECTION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; MICE, INBRED BALB C; MICROTUBULE-ASSOCIATED PROTEINS; PODOCYTES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIROLIMUS; TIME FACTORS;

EID: 84939877617     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-014-2090-7     Document Type: Article

References (38)

1. Zhuang L, Li M, Yu C, Li C, Zhao M, Lu M, Zheng T, Zhang R, Zhao W, Bao Y, Xiang K, Jia W, Wang N, Liu L (2014) The Leu72Met polymorphism of the GHRL gene prevents the development of diabetic nephropathy in Chinese patients with type 2 diabetes mellitus. Mol Cell Biochem 387:19–25
2. Lasaridis AN, Sarafidis PA (2003) Diabetic nephropathy and antihypertensive treatment: what are the lessons from clinical trials? Am J Hypertens 16:689–697
3. Lee JW, Brancati FL, Yeh HC (2011) Trends in the prevalence of type 2 diabetes in Asians versus whites: results from the United States National Health Interview Survey, 1997–2008. Diabetes Care 34:353–357
4. Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH (2004) Progression of nephropathy in type 2 diabetic patients. Kidney Int 66:1596–1605
5. Parving HH (2001) Diabetic nephropathy: prevention and treatment. Kidney Int 60:2041–2055
6. Jerums G, Panagiotopoulos S, Premaratne E, MacIsaac RJ (2009) Integrating albuminuria and GFR in the assessment of diabetic nephropathy. Nat Rev 5:397–406
7. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T (2005) Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28:164–176
8. White KE, Bilous RW, Marshall SM, Nahas EI, Remuzzi M, Piras G, De Cosmo S, Viberti G (2002) Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes 51:3083–3089
9. Arya A, Yadav HN, Sharma PL (2011) Involvement of vascular endothelial nitric oxide synthase in development of experimental diabetic nephropathy in rats. Mol Cell Biochem 354:57–66
10. Wiggins RC (2007) The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 71:1205–1214
11. Vogelmann SU, Nelson WJ, Myers BD, Lemley KV (2003) Urinary excretion of viable podocytes in health and renal disease. Am J Physiol 285:F40–F48
12. Skoberne A, Konieczny A, Schiffer M (2009) Glomerular epithelial cells in the urine: what has to be done to make them worthwhile? Am J Physiol 296:F230–F241
13. Levine B, Klionsky DJ (2004) Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 6:463–477
14. Hartleben B, Godel M, Meyer-Schwesinger C, Liu S, Ulrich T, Kobler S, Wiech T, Grahammer F, Arnold SJ, Lindenmeyer MT, Cohen CD, Pavenstadt H, Kerjaschki D, Mizushima N, Shaw AS, Walz G, Huber TB (2010) Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. Clin Invest 120:1084–1096
15. Noda T, Ohsumi Y (1998) Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J Biol Chem 273(8):3963–3966
16. Hartford CM, Ratain MJ (2007) Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther 82:381–388
17. Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, Allison DB, Cruzen C, Simmons HA, Kemnitz JW, Weindruch R (2009) Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 325:201–204
18. Eid AA, Ford BM, Bhandary B, de Cavaglieri Cassia R, Block K, Barnes JL, Gorin Y, Choudhury GG, Abboud HE (2013) Mammalian target of rapamycin regulates Nox4-mediated podocyte depletion in diabetic renal injury. Diabetes 62:2935–2947
19. Fang L, Zhou Y, Cao H, Wen P, Jiang L, He W, Dai C, Yang J (2013) Autophagy attenuates diabetic glomerluar damage through protection of hyperglycemia-induced podocyte injury. PLoS One 8:e60546
20. Sanchez AP, Zhao J, You Y, Decleves AE, Diamond-Stanic M, Sharma K (2011) Role of the USF1 transcription factor in diabetic kidney disease. Am J Physiol 301:F271–F279
21. Weibel E (1979) Stereologic methods. Practical methods for biological. Academic Press, London, p 415
22. Zhao J, Huang Y, Song Y, Zhao X, Jin J, Wang J, Huang L (2009) Low osmolar contrast medium induces cellular injury and disruption of calcium homeostasis in rat glomerular endothelial cells in vitro. Toxicol Lett 185:124–131
23. Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124:471–484
24. Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev 12:21–35
25. Chew GS, Myers S, Shu-Chien AC, Muhammad TS (2014) Interleukin-6 inhibition of peroxisome proliferator-activated receptor alpha expression is mediated by JAK2-and PI3K-induced STAT1/3 in HepG2 hepatocyte cells. Mol Cell Biochem 388:25–37
26. Yang Y, Wang J, Qin L, Shou Z, Zhao J, Wang H, Chen Y, Chen J (2007) Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol 27:495–502
27. Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, Alperovich G, Rama I, Vidal A, Grinyo JM (2006) Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 17:1395–1404
28. Mori H, Inoki K, Masutani K, Wakabayashi Y, Komai K, Nakagawa R, Guan KL, Yoshimura A (2009) The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem Biophys Res Commun 384:471–475
29. Gattone VH, Sinders RM, Hornberger TA, Robling AG (2009) Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis. Kidney Int 76:178–182
30. Shillingford JM, Piontek KB, Germino GG, Weimbs T (2010) Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol 21:489–497
31. Chen G, Chen H, Wang C, Peng Y, Sun L, Liu H, Liu F (2012) Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts. PLoS ONE 7:e33626
32. Baehrecke EH (2005) Autophagy: dual roles in life and death? Nat Rev Mol Cell Biol 6:505–510
33. Inoki K, Mori H, Wang J, Suzuki T, Hong S, Yoshida S, Blattner SM, Ikenoue T, Ruegg MA, Hall MN, Kwiatkowski DJ, Rastaldi MP, Huber TB, Kretzler M, Holzman LB, Wiggins RC, Guan KL (2011) mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest 121:2181–2196
34. Godel M, Hartleben B, Herbach N, Liu S, Zschiedrich S, Lu S, Debreczeni-Mor A, Lindenmeyer MT, Rastaldi MP, Hartleben G, Wiech T, Fornoni A, Nelson RG, Kretzler M, Wanke R, Pavenstadt H, Kerjaschki D, Cohen CD, Hall MN, Ruegg MA, Inoki K, Walz G, Huber TB (2011) Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 121:2197–2209
35. Lu MK, Gong XG, Guan KL (2011) mTOR in podocyte function: is rapamycin good for diabetic nephropathy? Cell Cycle 10:3415–3416
36. Diekmann F, Campistol JM (2006) Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks. Nephrol Dial Transplant 21:562–568
37. Torras J, Herrero-Fresneda I, Gulias O, Flaguer M, Vidal A, Cruzado JM, Lioberas N, Franguesa MI, Grinyo JM (2009) Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage? Nephrol Dial Transplant 24:3632–3640
38. Palma HE, Wolkmer P, Gallio M, Correa MMB, Schmatz R, Thome GR, Pereira LB, Castro VSP, Pereira AB, Bueno A (2014) Oxidative stress parameters in blood, liver, and kidney of diabetic rats treated with curcumin and/or insulin. Mol Cell Biochem 386:199–210